US ETFARK· ARKG· Active
ARK Genomic Revolution ETF
Issuer: ARK Invest · Expense 0.75%
1Y Return
44.2%
YTD Return
4.5%
3Y CAGR
44.4%
5Y CAGR
44.4%
1Y Volatility
41.0%
1Y Sharpe
1.00
Max Drawdown
-27.5%
Close
$30.48
Profile
Asset class: equity
Region: GLOBAL
Currency exposure: native
Monthly dividend: No
Leveraged: No
Pension-eligible: No
ISA-eligible: No
Themes
theme-genomicstheme-biotech
Related Inteliview Articles (2)
Pfizer Acquires Obesity Biotech Metsera, Enters GLP-1 War as Trump Medicare Coverage Launches
Pfizer acquires obesity biotech Metsera for billions, making a serious bid for the GLP-1 market. The…
May 5, 2026
Lilly and Novo Nordisk Locked In as Beneficiaries — Medicare to Cover GLP-1 Obesity Drugs for the First Time in July
Trump announced Medicare will cover Ozempic, Wegovy, and Zepbound at a $50 patient copay starting Ju…
May 2, 2026
Holdings — coming soon
US ETF holdings will be backfilled from issuer-direct sources (SPDR/iShares/Vanguard CSV feeds) and SEC N-PORT filings in Phase 3.3. Once available, the Wall Street guru × constituent overlap widget will render here.
Distribution history — Phase 2
Will appear once SEIBro distribution data is loaded.
Gurus holding this ETF — Phase 4
Will appear once 13F holdings data is joined in.
Metrics as of 2026-05-09 · Last close 2026-05-08